bortezomib krka 1 mg powder for solution for injection
krka, d.d., novo mesto - bortezomib - powder for solution for injection - 1 milligram(s) - bortezomib
bortezomib krka 3.5 mg powder for solution for injection
krka, d.d., novo mesto - bortezomib - powder for solution for injection - 3.5 milligram(s) - bortezomib
olmesartan/hydrochlorothiazide krka 40 mg/25 mg film-coated tablets
krka, d.d., novo mesto - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 40 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics
olmesartan/hydrochlorothiazide krka 40 mg/12.5 mg film-coated tablets
krka, d.d., novo mesto - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 40 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics
ezetimibe krka 10 mg tablets
krka, d.d., novo mesto - ezetimibe - tablet - 10 milligram(s) - other lipid modifying agents; ezetimibe
clopidogrel krka d.d. (previously zopya)
krka, d.d., novo mesto - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35days), ischaemic stroke (from 7days until less than 6months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.
rivaroxaban krka 10 mg film-coated tablets
krka, d.d., novo mesto - rivaroxaban - film-coated tablet - 10 milligram(s) - rivaroxaban
donepezil krka 10 milligram orodispersible tablet
krka d.d., novo mesto - donepezil hydrochloride - orodispersible tablet - 10 milligram
donepezil krka 5 milligram orodispersible tablet
krka d.d., novo mesto - donepezil hydrochloride - orodispersible tablet - 5 milligram
valsartan krka 40mg film-coated tablets
krka dd novo mesto Šmarješka cesta 6, 8501 novo mesto, slovenia - valsartan - film-coated tablet - valsartan 40 mg - agents acting on the renin-angiotensin system